Patients with or receiving potentially cardiotoxic treatment for cancer are susceptible to
developing decrements in left ventricular mass, diastolic function, or systolic function. They …

This paper aims to empower and inform cardio-oncologists by providing a practical guide to
the clinical application of cardiac magnetic resonance (CMR) in the rapidly evolving field of …

Background Trastuzumab improves dramatically the prognosis of HER2‐positive breast
cancer patients, but it may lead to cardiotoxicity with left ventricular (LV) systolic dysfunction …

Background Our objectives were to evaluate the temporal changes in CMR-based strain
imaging, and examine their relationship with left ventricular ejection fraction (LVEF), in …

Aims An improved understanding of the pathophysiology of trastuzumab-mediated
cardiotoxicity is required to improve outcomes of patients with human epidermal growth …

Background Left ventricular dysfunction and cardiomyopathy are well documented adverse
effects associated with chemotherapy agents. Limited information exists regarding the …

Background: There is increasing evidence that right ventricular ejection fraction (RVEF) may
provide incremental value to left ventricular (LV) ejection fraction for the prediction of major …

Opinion statement Early detection and treatment of cardiotoxicity from cancer therapies is
key to preventing a rise in adverse cardiovascular outcomes in cancer patients. Over …

2D (Two-dimensional), 3D (Three-dimensional), ASE (American Society of
Echocardiography), CAC (Coronary artery calcium), CCT (Cardiovascular computed …

The use of chemotherapy medicines for breast cancer (BC) has been associated with an
increased risk of cardiotoxicity. In recent years, there have been growing interests regarding …